MedTechbloggen

Antidopning: Kinas 2010 Prohibited List från Kinas FDA.

“In accordance with UNESCO International Convention against Doping in Sport and the Anti-doping Regulations of the State Council of China, the General Administration of Sport of China, the Ministry of Commerce, the Ministry of Health, the General Administration of Customs and the State Food and Drug Administration recently jointly issued an announcement, which released the 2010 Prohibited List.

The Announcement requires that each relevant department should do a good job in the supervision of the production, distribution, import and export, and the use of the substances in the 2010 Prohibited List in accordance with requirements of the Anti-doping Regulations of the State Council. The import and export of anabolic agents and peptide hormones shall follow Provisions for the Import and Export of Anabolic Agents and Peptide Hormones(interim).”

Oj!

“On the morning of March 3, 2010, Shao Mingli, Commissioner of the State Food and Drug Administration, met with visiting Prof. Baiba Rozentale, Health Minister of Latvia, and Ms. Ingrida Levrence, Ambassador Extraordinary and Plenipotentiary of the Republic of Latvia to P.R. China and discussed the mutual cooperation in the field of drug supervision.”

Kinas “läkemedelsverk” höjer aktiviteten inom kosmetikaområdet:

“The State Food and Drug Administration (SFDA) recently issued Measures for Cosmetic Administrative Licensing Testing and Measures for Qualification of Cosmetic Administrative Licensing Testing Institutions.

Measures for Cosmetic Administrative Licensing Testing specifies the relevant responsibilities of administrative licensing testing. The Measures, comprising eight chapters and 31 articles, came into effect as of February 11, 2010. The Measures shall prevail where previous documents are inconsistent with it. The Requirements for Cosmetic Administrative Licensing Testing issued at the same time consists of six chapters and 39 articles.

Measures for Qualification of Cosmetic Administrative Licensing Testing Institutions specifies the qualification of cosmetic administrative licensing testing institutions. The measures, comprising five chapters and 23 articles, came into effect as of February 11, 2010. The Measures shall prevail where previous documents are inconsistent with it. The Requirements for Qualification of Cosmetic Administrative Licensing Testing Institutions issued at the same time consists of five chapters and 31 articles.”

Kosmetik i Kina. Nya guidelines utgivna av SFDA.

“In order to meet the needs of administrative licensing for cosmetics, intensify supervision on the naming of cosmetics, ensure scientific and standardized naming of cosmetics, and protect the rights and interests of consumers, the State Food and Drug Administration (SFDA) formulated and issued Requirements on Naming of Cosmetics and Guide to the Naming of Cosmetics in accordance with Regulations Concerning the Hygiene Supervision Over Cosmetics and the rules for the implementation of the Regulations.

To better implement Requirements on Naming of Cosmetics and Guide to the Naming of Cosmetics, SFDA released Notice on Issues Concerning Implementation of Requirements on Naming of Cosmetics and Guide to the Naming of Cosmetics.”

Som ren information bjuder MedTechbloggen på en sammanfattande information om 2010 års Kininesiska Pharm:

2010 Chinese Pharmacopoeia, the 9th edition of the Pharmacopoeia of the People’s Republic of China, contains a total of 4567 monographs, including 1386 new admissions; in Volume I, it contains 2165 monographs of Chinese materia medica and prepared slices of Chinese crude drugs, vegetable oil/ fats and extractives, traditional Chinese patent medicines and simple preparations, with 1019 new admissions, and 634 revisions; Volume II includes 2271 monographs of chemical drugs, antibiotics, biochemical preparations, radiopharmaceuticals and excipients, with 330 new admissions and 1500 revisions; Volume III contains 131 monographs of biological products, with 37 new admissions and 94 revisions; and there are 47 new admissions and 154 revisions in the Appendix.

Pressrelease från Kinesiska Läkemedelverket, berör både Medicinteknik och Läkemedel:

“In order to strengthen the supervision and management to medial sodium hyaluronate (hyaluronic acid sodium) products, further standardize the application and approval procedure and ensure the safety and effectiveness of drugs and medical devices, the State Food and Drug Administration (SFDA) recently released an announcement on management classification of medial sodium hyaluronate in accordance with Drug Administration Law of the People’s Republic of China, Regulations for Supervision and Administration of Medical Devices

According to different clinical applications (indications), the announcement defines the management to medial sodium hyaluronate (hyaluronic acid sodium) products: Products with definite pharmacological effects for the treatment of arthritis, xerophthalmia and skin ulcer shall be managed as pharmaceuticals; Products used in ophthalmic operation aiding, surgical adhesion prevention and tissue augmentation shall be managed as medical devices.”

Nytt från Kina;

“In order to intensify supervision on medical device manufacturing, standardize quality management systems for medical device manufacturing, strengthen the management of medical device GMP inspection, in accordance with Regulations for Supervision and Administration of Medical Devices and other related regulations, the State Food and Drug Administration (SFDA) formulated Good Manufacturing Practice for Medical Devices (interim) and Requirements for Medical Device GMP Inspection (interim).

Good Manufacturing Practice for Medical Devices (interim) comprises 13 chapters, 69 articles and will take effect as of January 1, 2011.”

MedTechbloggen förmedlar information från det “kinesiska Läkemedelsveket”:

“The State Food and Drug Administration (SFDA) formulated Medical Device GMP Detailed Rules for Sterile Medical Devices (interim), Medical Device GMP Inspection Standards for Sterile Medical Devices (interim), Medical Device GMP Detailed Rules for Implantable Medical Devices (interim) and Medical Device GMP Inspection Standards for Implantable Medical Device (interim) and recently issued notices on relevant requirements, for the purposes of enforcing Good Manufacturing Practice for Medical Devices (interim), standardizing the production quality management systems and the supervision and inspection of sterile medical devices and implantable medical device.”

“Since soliciting opinions on revised Good Manufacturing Practice for Pharmaceutical Products (draft for comment) in September 2009, the State Food and Drug Administration (SFDA) has received timely feedback from all-walks of life in the society. On the basis of the feedback, SFDA organized the re-revision of Good Manufacturing Practice for Pharmaceutical Products (draft for comment). The revised Good Manufacturing Practice for Pharmaceutical Products (2nd draft for comment) and the appendix are now soliciting public opinions. Opinions shall be provided in written form to the Department of Drug Safety & Inspection of SFDA before December 20, 2009.”

Säljer du infusionspumpar på Kina kan det vara bra att titta närmare på detta:

The State Food and Drug Administration (SFDA) released the third issue of 2009 National Medical Device Quality Announcement on November 17,2009 and publicized the quality sampling and testing results of disposable infusion pumps.